{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:14:16Z","timestamp":1760904856612,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.critrevonc.2021.103336","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:28:18Z","timestamp":1618792098000},"page":"103336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review"],"prefix":"10.1016","volume":"162","author":[{"given":"Hal","family":"Hirte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-3758","authenticated-orcid":false,"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-1937","authenticated-orcid":false,"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103336_bib0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2005.07.117","article-title":"Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study","volume":"100","author":"Alberts","year":"2006","journal-title":"Gynecol. Oncol."},{"year":"2021","series-title":"Prospero","author":"Anon","key":"10.1016\/j.critrevonc.2021.103336_bib0010"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0015","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e31816060ce","article-title":"CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer","volume":"31","author":"Berek","year":"2008","journal-title":"J Immunother."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ijgc-00009577-200602001-00012","article-title":"Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study","volume":"16","author":"Bolis","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0035","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"year":"2020","series-title":"Soft Tissue Sarcoma Statistics. Toronto, ON: Canadian Cancer society","author":"Canadian Cancer Society\u2019s Steering Committee on Cancer Statistics","key":"10.1016\/j.critrevonc.2021.103336_bib0040"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0045","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0050","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-1) randomized study","volume":"22","author":"De Placido","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0060","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"Du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"suppl, abstr 5512","key":"10.1016\/j.critrevonc.2021.103336_bib0065","first-page":"33","article-title":"Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study","volume":"33","author":"Ferron","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","volume":"29","author":"Friedlander","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonzalez Martin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0080","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6602037","article-title":"Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study","volume":"91","author":"Hall","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0105","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/igc.0000000000000602","article-title":"Pazopanib maintenance therapy in east asian women with advanced epithelial ovarian Cancer: results from AGO-OVAR16 and an east asian study","volume":"28","author":"Kim","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0115","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2012.04.050","article-title":"Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV","volume":"126","author":"Meier","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0140","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7150\/ijms.1.116","article-title":"A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission?","volume":"1","author":"Nicoletto","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0150","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/Gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0155","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0160","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the after-6 protocol 1","volume":"27","author":"Pecorelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0165","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0170","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ijgc-00009577-200311001-00012","article-title":"Intraperitoneal cisplatin versus no further treatment: 8-Year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy","volume":"13","author":"Piccart","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0180","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0185","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Ray-Coquard","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating parp-inhibitors in primary and Recurrent Ovarian Cancer: a meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0195","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0200","unstructured":"Sch\u00fcnemann, H., Brozek, J., Guyatt, G., Oxman, A.D. (Eds.). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. (updated October 2013)."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0205","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP inhibitors in ovarian cancer: \u201cClass Action\u201d or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0215","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0220","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","volume":"50","author":"van der Burg","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103336_bib0225","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2012.44.9116","article-title":"Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","volume":"32","author":"Vergote","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0235","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","article-title":"Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer","volume":"155","author":"Vergote","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0240","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial","volume":"20","author":"Vergote","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103336_bib0245","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/IGC.0000000000001258","article-title":"Angiogenesis inhibitors for the treatment of ovarian Cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2018","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:35:30Z","timestamp":1760902530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":49,"alternative-id":["S1040842821001244"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103336","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103336"}}